
Browsing restrictions can be lifted for a fee.
Pacific Hospital Supply Co., Ltd., together with its subsidiaries, manufactures, processes, and sells medical disposable products and equipment in Taiwan. The company's disposable medical devices include tubings, bags, bottles, closed wound drainage systems, surgical suction instruments, respiratory therapy products, and other products. It also provides medical gas systems, such as medical gas outlets, secondary equipment, accessories, and pipeline equipment, as well as pipeline system design and maintenance services. Pacific Hospital Supply Co., Ltd. offers its products for health c are industry clients. The company also exports its products to approximately 80 countries and regions. Pacific Hospital Supply Co., Ltd. was founded in 1977 and is headquartered in Miaoli, Taiwan.
4126
太醫
-0.50%
(-0.00)
The most recent financial report for 太醫 (4126) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4126's short-term business performance and financial health. For the latest updates on 4126's earnings releases, visit this page regularly.
According to historical valuation range analysis, 太醫 (4126)'s current price-to-earnings (P/E) ratio is 12.82, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 太醫 (4126) reported an Operating Profit of 129.13M with an Operating Margin of 19.59% this period, representing a growth of 5.08% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 太醫 (4126) announced revenue of 659.14M, with a Year-Over-Year growth rate of 13.81%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 太醫 (4126) held Total Cash and Cash Equivalents of 511.8M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 太醫 (4126) achieved the “three margins increasing” benchmark, with a gross margin of 30.17%%, operating margin of 19.59%%, and net margin of 19.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4126's profit trajectory and future growth potential.
According to the past four quarterly reports, 太醫 (4126)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.8. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
太醫 (4126)'s Free Cash Flow (FCF) for the period is -4.25M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 87.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.